5-131159550-C-T
Position:
Variant summary
Our verdict is Pathogenic. Variant got 16 ACMG points: 16P and 0B. PM1PM2PP3_StrongPP5_Very_Strong
The NM_005340.7(HINT1):c.278G>A(p.Gly93Asp) variant causes a missense change. The variant allele was found at a frequency of 0.00000682 in 1,613,686 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★).
Frequency
Genomes: 𝑓 0.000013 ( 0 hom., cov: 32)
Exomes 𝑓: 0.0000062 ( 0 hom. )
Consequence
HINT1
NM_005340.7 missense
NM_005340.7 missense
Scores
10
8
1
Clinical Significance
Conservation
PhyloP100: 7.18
Genes affected
HINT1 (HGNC:4912): (histidine triad nucleotide binding protein 1) This gene encodes a protein that hydrolyzes purine nucleotide phosphoramidates substrates, including AMP-morpholidate, AMP-N-alanine methyl ester, AMP-alpha-acetyl lysine methyl ester, and AMP-NH2. The encoded protein interacts with these substrates via a histidine triad motif. This gene is considered a tumor suppressor gene. In addition, mutations in this gene can cause autosomal recessive neuromyotonia and axonal neuropathy. There are several related pseudogenes on chromosome 7. Several transcript variants have been observed. [provided by RefSeq, Dec 2015]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 16 ACMG points.
PM1
In a domain HIT (size 108) in uniprot entity HINT1_HUMAN there are 6 pathogenic changes around while only 0 benign (100%) in NM_005340.7
PM2
Very rare variant in population databases, with high coverage;
PP3
MetaRNN computational evidence supports a deleterious effect, 0.972
PP5
Variant 5-131159550-C-T is Pathogenic according to our data. Variant chr5-131159550-C-T is described in ClinVar as [Likely_pathogenic]. Clinvar id is 37318.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
HINT1 | NM_005340.7 | c.278G>A | p.Gly93Asp | missense_variant | 3/3 | ENST00000304043.10 | NP_005331.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
HINT1 | ENST00000304043.10 | c.278G>A | p.Gly93Asp | missense_variant | 3/3 | 1 | NM_005340.7 | ENSP00000304229.5 |
Frequencies
GnomAD3 genomes AF: 0.0000132 AC: 2AN: 151992Hom.: 0 Cov.: 32
GnomAD3 genomes
AF:
AC:
2
AN:
151992
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.0000199 AC: 5AN: 251344Hom.: 0 AF XY: 0.0000147 AC XY: 2AN XY: 135836
GnomAD3 exomes
AF:
AC:
5
AN:
251344
Hom.:
AF XY:
AC XY:
2
AN XY:
135836
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.00000616 AC: 9AN: 1461694Hom.: 0 Cov.: 31 AF XY: 0.00000550 AC XY: 4AN XY: 727178
GnomAD4 exome
AF:
AC:
9
AN:
1461694
Hom.:
Cov.:
31
AF XY:
AC XY:
4
AN XY:
727178
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0000132 AC: 2AN: 151992Hom.: 0 Cov.: 32 AF XY: 0.0000135 AC XY: 1AN XY: 74232
GnomAD4 genome
AF:
AC:
2
AN:
151992
Hom.:
Cov.:
32
AF XY:
AC XY:
1
AN XY:
74232
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Bravo
AF:
ExAC
AF:
AC:
3
EpiCase
AF:
EpiControl
AF:
ClinVar
Significance: Pathogenic/Likely pathogenic
Submissions summary: Pathogenic:3
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
Autosomal recessive axonal neuropathy with neuromyotonia Pathogenic:2
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | May 15, 2023 | Variant summary: HINT1 c.278G>A (p.Gly93Asp) results in a non-conservative amino acid change located in the HIT-like domain (IPR011146) of the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 2e-05 in 251344 control chromosomes (gnomAD). c.278G>A has been reported in the literature as a compound heterozygous genotype in individuals affected with Autosomal Recessive Axonal Neuropathy With Neuromyotonia with a Charcot-Marie-Tooth disease presentation, including a case where it was found in trans with a pathogenic variant and segregated with disease in a family, and also in an individual undergoing WES whose phenotype was not specified (e.g. Zimon_2012, Lin_2020, Stranneheim_2021). These data indicate that the variant is likely associated with disease. A publication reporting experimental evidence evaluating an impact on protein function found that the variant protein exists in the monomeric state instead of forming a dimer and resulted in a catalytic activity <10% of normal (Shah_2018). The following publications have been ascertained in the context of this evaluation (PMID: 31832804, 29787766, 33726816, 22961002). One clinical diagnostic laboratory has submitted a clinical-significance assessment for this variant to ClinVar after 2014 and classified the variant as likely pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. - |
Pathogenic, no assertion criteria provided | literature only | OMIM | Oct 01, 2012 | - - |
Inborn genetic diseases Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Dec 18, 2020 | The p.G93D variant (also known as c.278G>A), located in coding exon 3 of the HINT1 gene, results from a G to A substitution at nucleotide position 278. The glycine at codon 93 is replaced by aspartic acid, an amino acid with similar properties. This mutation has been detected in a compound heterozygous state in individuals presenting with a Charcot-Marie-Tooth disease phenotype (Zimo M et al. Nat Genet, 2012 Oct;44:1080-3; Lin S et al. Neurogenetics, 2020 04;21:79-86). Additionally, functional studies have shown that this alteration appears to lead to impaired substrate binding and reduced catalytic activity (Shah RM et al. J Mol Biol, 2018 08;430:2709-2721). This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Based on the majority of available evidence to date, this variant is likely to be pathogenic. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Pathogenic
BayesDel_addAF
Pathogenic
D
BayesDel_noAF
Pathogenic
CADD
Uncertain
DANN
Uncertain
DEOGEN2
Pathogenic
D
Eigen
Uncertain
Eigen_PC
Uncertain
FATHMM_MKL
Uncertain
D
LIST_S2
Uncertain
D
M_CAP
Pathogenic
D
MetaRNN
Pathogenic
D
MetaSVM
Pathogenic
D
MutationAssessor
Pathogenic
M
PrimateAI
Uncertain
T
PROVEAN
Pathogenic
D
REVEL
Pathogenic
Sift
Uncertain
D
Sift4G
Uncertain
D
Polyphen
B
Vest4
MutPred
Gain of solvent accessibility (P = 0.0648);
MVP
MPC
ClinPred
D
GERP RS
RBP_binding_hub_radar
RBP_regulation_power_radar
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at